What is the current Price Target for the Outlook Therapeutics, Inc. stock?

The average Outlook Therapeutics, Inc. target price is $10.20. This is 716.00% higher than the current stock price. The highest price target is 1,820.00%, the lowest is 140.00%. 5 Analysts have issued a price target Outlook Therapeutics, Inc. 2026 .

How high will the Outlook Therapeutics, Inc. stock rise?

No reliable answer can be given as to how high the Outlook Therapeutics, Inc. stock will rise. The performance of stocks, including the Outlook Therapeutics, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Outlook Therapeutics, Inc. stock today?

The performance of Outlook Therapeutics, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Outlook Therapeutics, Inc. stock fall?

The decline in Outlook Therapeutics, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Outlook Therapeutics, Inc. Forecast, price target & analysts

$1.24

0.80% today

Nasdaq, Apr 03, 06:47 pm CET

ISIN

US69012T2069

Symbol

OTLK

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Outlook Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Outlook Therapeutics, Inc. Classifications & Recommendation:

Buy

80%

Hold

20%

Outlook Therapeutics, Inc. Price Target

Target Price	$10.20
Price	$1.25
Potential	716.00% register free of charge
Number of Estimates	5

	5 Analysts have issued a price target Outlook Therapeutics, Inc. 2026 . The average Outlook Therapeutics, Inc. target price is $10.20. This is 716.00% register free of charge higher than the current stock price. The highest price target is $24.00 1,820.00% register free of charge , the lowest is $3.00 140.00% register free of charge .
	A rating was issued by 5 analysts: 4 Analysts recommend Outlook Therapeutics, Inc. to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Outlook Therapeutics, Inc. stock has an average upside potential 2026 of 716.00% register free of charge . Most analysts recommend the Outlook Therapeutics, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Sep '24	2025 Estimates
Earnings Per Share $	-4.06	-0.72
	13.98%	82.27%
P/E		negative
EV/Sales		9.03

1 Analysts have issued a Outlook Therapeutics, Inc. forecast for earnings per share. The average Outlook Therapeutics, Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-4.06	13.98%
2025	$-0.72 82.27% Unlock
2026	$-0.95 31.94% Unlock
2027	$0.62 165.26% Unlock
2028	$2.37 282.26% Unlock
2029	$3.24 36.71% Unlock

Current	-0.16	94.67%
2025	-1.74 987.50% Unlock
2026	-1.32 24.14% Unlock
2027	2.02 253.03% Unlock
2028	0.53 73.76% Unlock
2029	0.39 26.42% Unlock

Outlook Therapeutics, Inc....

Current Outlook Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Ascendiant Capital	Locked ➜ Locked	Locked	Feb 24 2025
Chardan Capital	Locked ➜ Locked	Locked	Feb 18 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Feb 18 2025
Guggenheim	Locked ➜ Locked	Locked	Jan 17 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jan 17 2025
Chardan Capital	Locked ➜ Locked	Locked	Dec 02 2024
BTIG	Locked ➜ Locked	Locked	Nov 29 2024

Analyst Rating	Date
Locked Ascendiant Capital: Locked ➜ Locked	Feb 24 2025
Locked Chardan Capital: Locked ➜ Locked	Feb 18 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Feb 18 2025
Locked Guggenheim: Locked ➜ Locked	Jan 17 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Jan 17 2025
Locked Chardan Capital: Locked ➜ Locked	Dec 02 2024
Locked BTIG: Locked ➜ Locked	Nov 29 2024

Discover more stocks with a high price target

Novo Nordisk 75.12%

Coinbase Global, Inc. 71.30%

BioNTech SE - ADR 48.29%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now